Advertisement
UK markets closed

  • NIKKEI 225

    38,385.73
    +29.67 (+0.08%)
     

  • HANG SENG

    19,073.71
    -41.35 (-0.22%)
     

  • CRUDE OIL

    78.81
    +0.79 (+1.01%)
     

  • GOLD FUTURES

    2,392.40
    +32.50 (+1.38%)
     

  • DOW

    39,893.65
    +335.54 (+0.85%)
     

  • Bitcoin GBP

    52,091.12
    +3,524.85 (+7.26%)
     

  • CMC Crypto 200

    1,389.92
    +121.97 (+9.62%)
     

  • NASDAQ Composite

    16,738.44
    +227.26 (+1.38%)
     

  • UK FTSE All Share

    4,596.71
    +13.48 (+0.29%)
     
Money:

How to claim expenses at work without breaking the rules

Knowing more about tax rules can save you money

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Equity Research
·2-min read

Neurocrine Biosciences (NBIX) reported $515.3 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 22.6%. EPS of $0.42 for the same period compares to -$0.79 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $512.21 million, representing a surprise of +0.60%. The company delivered an EPS surprise of -59.62%, with the consensus EPS estimate being $1.04.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Revenues- Collaboration revenue: $6.30 million versus $7.68 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +23.5% change.

  • Revenues- Product sales, net: $509 million compared to the $505.50 million average estimate based on nine analysts. The reported number represents a change of +22.6% year over year.

  • INGREZZA product sales, net: $506 million compared to the $505 million average estimate based on eight analysts. The reported number represents a change of +23.3% year over year.

View all Key Company Metrics for Neurocrine here>>>

Shares of Neurocrine have returned -0.2% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research